Cargando…

PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway

Adverse cardiac remodeling, including cardiac fibrosis, after myocardial infarction (MI) is a major cause of long-term heart failure. 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), an enzyme that regulates glucose metabolism, also plays an important role in various fibrotic and card...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qian, Zong, Xiao, Zhuang, Lingfang, Pan, Roubai, Tudi, Xierenayi, Fan, Qin, Tao, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377206/
https://www.ncbi.nlm.nih.gov/pubmed/37509108
http://dx.doi.org/10.3390/biom13071072
_version_ 1785079460542808064
author Yang, Qian
Zong, Xiao
Zhuang, Lingfang
Pan, Roubai
Tudi, Xierenayi
Fan, Qin
Tao, Rong
author_facet Yang, Qian
Zong, Xiao
Zhuang, Lingfang
Pan, Roubai
Tudi, Xierenayi
Fan, Qin
Tao, Rong
author_sort Yang, Qian
collection PubMed
description Adverse cardiac remodeling, including cardiac fibrosis, after myocardial infarction (MI) is a major cause of long-term heart failure. 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), an enzyme that regulates glucose metabolism, also plays an important role in various fibrotic and cardiovascular diseases. However, its effects on MI remain unknown. Here, PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) and a permanent left anterior descending ligation mouse model were used to explore the functional role of PFKFB3 in MI. We showed that PFKFB3 expression increased significantly in the area of cardiac infarction during the early phase after MI, peaking on day 3. 3PO treatment markedly improved cardiac function, accompanied by decreased infarction size and collagen density in the infarct area. Meanwhile, 3PO attenuated cardiac fibrosis after MI by reducing the expression of collagen and fibronectin in murine hearts. Notably, 3PO reduced PFKFB3 expression and inhibited the transforming growth factor-beta 1/mothers against the decapentaplegic homolog 2/3 (TGF-β1/SMAD2/3) signaling pathway to inhibit cardiac fibrosis after MI. Moreover, PFKFB3 expression in neonatal rat cardiac fibroblasts (NRCFs) increased significantly after MI and under hypoxia, whereas 3PO alleviated the migratory capacity and activation of NRCFs induced by TGF-β1. In conclusion, 3PO effectively reduced fibrosis and improved adverse cardiac remodeling after MI, suggesting PFKFB3 inhibition as a novel therapeutic strategy to reduce the incidence of chronic heart failure following MI.
format Online
Article
Text
id pubmed-10377206
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103772062023-07-29 PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway Yang, Qian Zong, Xiao Zhuang, Lingfang Pan, Roubai Tudi, Xierenayi Fan, Qin Tao, Rong Biomolecules Article Adverse cardiac remodeling, including cardiac fibrosis, after myocardial infarction (MI) is a major cause of long-term heart failure. 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), an enzyme that regulates glucose metabolism, also plays an important role in various fibrotic and cardiovascular diseases. However, its effects on MI remain unknown. Here, PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) and a permanent left anterior descending ligation mouse model were used to explore the functional role of PFKFB3 in MI. We showed that PFKFB3 expression increased significantly in the area of cardiac infarction during the early phase after MI, peaking on day 3. 3PO treatment markedly improved cardiac function, accompanied by decreased infarction size and collagen density in the infarct area. Meanwhile, 3PO attenuated cardiac fibrosis after MI by reducing the expression of collagen and fibronectin in murine hearts. Notably, 3PO reduced PFKFB3 expression and inhibited the transforming growth factor-beta 1/mothers against the decapentaplegic homolog 2/3 (TGF-β1/SMAD2/3) signaling pathway to inhibit cardiac fibrosis after MI. Moreover, PFKFB3 expression in neonatal rat cardiac fibroblasts (NRCFs) increased significantly after MI and under hypoxia, whereas 3PO alleviated the migratory capacity and activation of NRCFs induced by TGF-β1. In conclusion, 3PO effectively reduced fibrosis and improved adverse cardiac remodeling after MI, suggesting PFKFB3 inhibition as a novel therapeutic strategy to reduce the incidence of chronic heart failure following MI. MDPI 2023-07-03 /pmc/articles/PMC10377206/ /pubmed/37509108 http://dx.doi.org/10.3390/biom13071072 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yang, Qian
Zong, Xiao
Zhuang, Lingfang
Pan, Roubai
Tudi, Xierenayi
Fan, Qin
Tao, Rong
PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway
title PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway
title_full PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway
title_fullStr PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway
title_full_unstemmed PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway
title_short PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway
title_sort pfkfb3 inhibitor 3po reduces cardiac remodeling after myocardial infarction by regulating the tgf-β1/smad2/3 pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377206/
https://www.ncbi.nlm.nih.gov/pubmed/37509108
http://dx.doi.org/10.3390/biom13071072
work_keys_str_mv AT yangqian pfkfb3inhibitor3poreducescardiacremodelingaftermyocardialinfarctionbyregulatingthetgfb1smad23pathway
AT zongxiao pfkfb3inhibitor3poreducescardiacremodelingaftermyocardialinfarctionbyregulatingthetgfb1smad23pathway
AT zhuanglingfang pfkfb3inhibitor3poreducescardiacremodelingaftermyocardialinfarctionbyregulatingthetgfb1smad23pathway
AT panroubai pfkfb3inhibitor3poreducescardiacremodelingaftermyocardialinfarctionbyregulatingthetgfb1smad23pathway
AT tudixierenayi pfkfb3inhibitor3poreducescardiacremodelingaftermyocardialinfarctionbyregulatingthetgfb1smad23pathway
AT fanqin pfkfb3inhibitor3poreducescardiacremodelingaftermyocardialinfarctionbyregulatingthetgfb1smad23pathway
AT taorong pfkfb3inhibitor3poreducescardiacremodelingaftermyocardialinfarctionbyregulatingthetgfb1smad23pathway